Corporate information
Registration country
Company type
Cancer drug development company.Funding rounds
Acquisition USD 10,200,000,000
USD 10,200,000,000 ( ) at USD 10,200,000,000 pre-money valuation
The deal includes USD5.8 billion in upfront payments, includingUSD2 billion in stock, as well as USD4 billion in cash-based earnouts, plus a return to shareholders of Stemcentrx of cash on hand.
| Investor | Profile | Country | Notes | |
|---|---|---|---|---|
|
Abbvie Inc | 10,200,000,000 (USD 10,200,000,000) Initial investment. |
Series G USD 250,000,000
USD 250,000,000 ( )
| Investor | Profile | Country | |
|---|---|---|---|
|
Artis Ventures | Venture capital firm |
Series F USD 200,000,000
USD 200,000,000 ( )
| Investor | Profile | Country | |
|---|---|---|---|
|
|
Artis Ventures | Venture capital firm |
Series C USD 23,530,000
USD 23,530,000 ( )
| Investor | Profile | Country | Notes | |
|---|---|---|---|---|
|
|
Artis Ventures | Venture capital firm | (Led the round.) |
| Investor | Profile | Country | Notes | |
|---|---|---|---|---|
|
OakHouse Partners | Initial investment. (via Alpha Fund) Exited. (Trade sale) |
Investment activity status
Not investing